11:59 AM EDT, 03/18/2024 (MT Newswires) -- GSK (GSK) said Saturday that results from the phase three Ruby study in adults with primary advanced or recurrent endometrial cancer showed Jemperli with chemotherapy significantly improved overall survival in the overall population.

The trial showed a 31% reduction in risk of death and 16.4-month improvement in median overall survival observed with the combination versus chemotherapy, the company said.

The study also showed a 37% reduction in risk of disease progression or death and 6-month improvement in median progression-free survival observed with the addition of Zejula to Jemperli maintenance, GSK said.

The company said it expects US Food and Drug Administration submission acceptance based on part 1 data for an expanded indication in the overall population in the first half of this year.

Price: 42.23, Change: +0.04, Percent Change: +0.10